| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 186,20 | 186,80 | 08:03 | |
| 186,20 | 186,80 | 08:00 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 188,80 | 3 | |||
| 187,60 | 88 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/4ab.htm [/URL] | ||||
| 88 | 187,40 | |||
| 3 | 186,00 | |||
| 12 | 167,60 | |||
| 7 | 150,00 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 110 | 0,827 | 91 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:00:23 | 188,60 | 19 |
| 17:00:23 | 188,60 | 26 |
| 16:54:49 | 189,40 | 85 |
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks | 12 | Reuters | ||
| 20.01. | Bernstein reiterates Market Perform rating on Abbvie stock at $225 target | 13 | Investing.com | ||
| ABBVIE Aktie jetzt für 0€ handeln | |||||
| 19.01. | The Smartest Dividend Stocks to Buy in 2026 With $1,000 Right Now -- Including Realty Income and AbbVie | 76 | The Motley Fool | ||
| 17.01. | AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit | 736 | AFX News | WASHINGTON (dpa-AFX) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific... ► Artikel lesen | |
| 16.01. | After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next? | 15 | FiercePharma |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel to Address Gastric Bleeding Risks | ACCESS Newswire | New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.Clopidogrel, currently sold under the brand name Plavix, was... ► Artikel lesen | |
| Di | Teva Pharmaceutical Industries Ltd: Will Forte Teams Up with Teva to Get Real About Huntington's Disease with 'Honestly HD' | GlobeNewswire (Europe) | Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington's disease (HD) and chorea through Teva's Honestly HD programHD is a rare, progressive genetic disorder often... ► Artikel lesen | |
| Di | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | GlobeNewswire (Europe) | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| Di | Roche-Aktie: Kampf gegen Eli Lilly und Novo Nordisk | sharedeals.de | In den vergangenen zehn Jahren tat sich die Roche-Aktie nicht durch eine besonders gute Kursentwicklung hervor. Doch in den letzten drei Monaten legte der Kurs des Schweizer Pharmariesen um über +25%... ► Artikel lesen | |
| Di | Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 | ACCESS Newswire | DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen |